BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations ...Middle East

- Global trial designed to study the safety, tolerability and efficacy of bemcentinib in combination with current standard of care – BERGEN, Norway, March 9, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase...

Hence then, the article about bergenbio announces first patient dosed in phase 1b 2a trial evaluating bemcentinib in 1st line non small cell lung cancer with stk11 mutations was published today ( Thursday 09/03/2023 - 01:40 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations )

Also on site :

• 'Euphoria' Shows Sydney Sweeney Masturbating and Topless on OnlyFans
• Kevin Hart Roast: Comedian Ends Katt Williams Beef as The Rock, Teyana Taylor and More Cracks Jokes About Hart’s Height and Filmography
• Millions of 'pandemic pets' are reaching midlife, but owners could miss a crucial opportunity to improve their pet's healthspan